Time for a little bit of centreing up on this SLA subject. The directors got themselves and the company into a pickle through moves that were not thought through to possible consequences. Vagif is an incredible person and has virtually done a miracle job in getting this company and the intellectual property it owns rights to into a very strong, a very strong position whereby it now is about to embark on another sector of what is an amazing journey. The patents, licences, manufacturing and marketing are all in place and are now about to take SLA (and shareholders) to another level of existence altogether. Jeez if this little Biotech hasn't got more legs and upside than most companies on the ASX then I wll go hee. All the stuff of dreams is still intact and just getting better. My sums show $360 million in sales next 12 months (without Bio A)at 70% profit and this is (at 7 times) about $12 @ share. OP is about to get caned in court leaving a deal with ANZ a certainty (or they will be caned)and Vagif will be back with another headdress of feathers for his already overloaded cap and Ropren (already labelled a potential blockbuster drug)being marketed by the specialist Russian and her 5 assistants all around Europe. The job is right and we just have to sit tight. Out of adversity comes wisdom and strength. It will be a new and dynamic Solagran with its tail in the air and a wind at its back very soon now...Stay Frosty...Stay the Course.
SLA Price at posting:
0.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)